PGE2-Induced CXCL12 Production and CXCR4 Expression Controls the Accumulation of Human MDSCs in Ovarian Cancer Environment

Abstract

Signals mediated by CXCL12 (SDF1) and its receptor CXCR4 are centrally involved in cancer progression, both directly by activating cancer cells and indirectly by inducing angiogenesis plus recruiting T regulatory and plasmacytoid dendritic immune cells. Here, we show that in ascites isolated from ovarian cancer patients, both CXCL12 and CXCR4 are controlled by the tumor-associated inflammatory mediator prostaglandin E₂ (PGE₂), which attracts myeloid-derived suppressor cells (MDSC) into the ascites microenvironment. In this setting, PGE₂ was essential both for expression of functional CXCR4 in cancer-associated MDSCs and for production of its ligand CXCL12. Frequencies of CD11b⁺CD14⁺CD33⁺CXCR4⁺ MDSCs closely correlated with CXCL12 and PGE₂ levels in patient ascites. MDSCs migrated toward ovarian cancer ascites in a CXCR4-dependent manner that required COX2 activity and autocrine PGE₂ production. Inhibition of COX2 or the PGE₂ receptors EP2/EP4 in MDSCs suppressed expression of CXCR4 and MDSC responsiveness to CXCL12 or ovarian cancer ascites. Similarly, COX2 inhibition also blocked CXCL12 production in the ovarian cancer environment and its ability to attract MDSCs. Together, our findings elucidate a central role for PGE₂ in MDSC accumulation triggered by the CXCL12-CXCR4 pathway, providing a powerful rationale to target PGE₂ signaling in ovarian cancer therapy. Cancer Res; 71(24); 7463–70. ©2011 AACR.